Trial · NCT03063632
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | Group I (Pembrolizumab, Interferon Gamma-1b) | 6 | Participants | ||
| Overall Response Rate (ORR) | Group II (Pembrolizumab, Interferon Gamma-1b) | 0 | Participants | ||
| Incidence of Adverse Events | Group I (Pembrolizumab, Interferon Gamma-1b) | 15 | Participants | ||
| Incidence of Adverse Events | Group II (Pembrolizumab, Interferon Gamma-1b) | 12 | Participants | ||
| Time to Response (TTR) | Group I (Pembrolizumab, Interferon Gamma-1b) | 126 | Inter-Quartile Range 106 to 463 | days | |
| Duration of Response (DOR) | Group I (Pembrolizumab, Interferon Gamma-1b) | 505.0 | 95% Confidence Interval 106.0 to NA | days | |
| Progression-free Survival (PFS) | Group I (Pembrolizumab, Interferon Gamma-1b) | 394.0 | 95% Confidence Interval 120.0 to 615.0 | days | |
| Progression-free Survival (PFS) | Group II (Pembrolizumab, Interferon Gamma-1b) | 196.5 | 95% Confidence Interval 32.0 to NA | days | |
| Event-free Survival (EFS) | Group I (Pembrolizumab, Interferon Gamma-1b) | 185.5 | 95% Confidence Interval 120.0 to 394.0 | days | |
| Event-free Survival (EFS) | Group II (Pembrolizumab, Interferon Gamma-1b) | 73.0 | 95% Confidence Interval 32.0 to NA | days | |
| Rate of Overall Response Duration Beyond 12 Months (ORR12) | Group I (Pembrolizumab, Interferon Gamma-1b) | 2 | Participants | ||
| Rate of Overall Response Duration Beyond 12 Months (ORR12) | Group II (Pembrolizumab, Interferon Gamma-1b) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03063632/results